Medical Department, St. Paul's Hospital Millennium Medical College, Addis Ababa, Ethiopia.
Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
Liver Int. 2017 Oct;37(10):1461-1467. doi: 10.1111/liv.13393. Epub 2017 Mar 23.
In the absence of liver biopsy, the World Health Organization recommends non-invasive tests, such as aspartate aminotransferase to platelet ratio index and FIB-4, to assess liver fibrosis in patients with chronic hepatitis B. However, these tests are not well validated in sub-Saharan Africa. Recently, a new marker, gamma-glutamyl transpeptidase to platelet ratio, was found to be more accurate in an African setting, but this needs confirmation in other cohorts.
A treatment program for chronic hepatitis B was initiated in Addis Ababa, Ethiopia, in 2015. Non-invasive tests were compared with transient elastography (Fibroscan 402, Echosense, France) using the following thresholds: no fibrosis (≤7.9 kPa), significant fibrosis (>7.9 kPa) and cirrhosis (>11.7 kPa). The diagnostic accuracy was estimated by calculating the area under the receiver operating characteristics curve.
Of 582 treatment-naïve patients, 141 (24.2%) had significant fibrosis and 90 (15.5%) had cirrhosis. The area under the receiver operating characteristics curve of aspartate aminotransferase to platelet ratio index, FIB-4 and gamma-glutamyl transpeptidase to platelet ratio was high both to diagnose significant fibrosis (0.79 [95% CI 0.75-0.84], 0.79 [95% CI 0.75-0.84], 0.80 [95% CI 0.75-0.85]) and cirrhosis (0.86 [95% CI 0.81-0.91], 0.86 [95% CI 0.81-0.91], 0.87 [95% CI 0.82-0.91]). The specificity was high for all tests (94%-100%); however, the sensitivity was poor both to detect fibrosis (10%-45%) and cirrhosis (10%-36%).
Aspartate aminotransferase to platelet ratio index, FIB-4 and gamma-glutamyl transpeptidase to platelet ratio had good diagnostic properties to detect liver fibrosis and cirrhosis in patients with chronic hepatitis B in East Africa. However, the sensitivity was low, and only 10% of patients with cirrhosis were detected using aspartate aminotransferase to platelet ratio index at the World Health Organization recommended threshold.
在缺乏肝活检的情况下,世界卫生组织建议使用非侵入性测试,如天冬氨酸转氨酶与血小板比值指数和 FIB-4,来评估慢性乙型肝炎患者的肝纤维化。然而,这些测试在撒哈拉以南非洲地区并未得到很好的验证。最近,一种新的标志物,即γ-谷氨酰转肽酶与血小板比值,在非洲环境中被发现更为准确,但这需要在其他队列中得到证实。
2015 年,在埃塞俄比亚亚的斯亚贝巴启动了慢性乙型肝炎治疗计划。使用以下阈值将非侵入性测试与瞬时弹性成像(Fibroscan 402,Echosense,法国)进行比较:无纤维化(≤7.9 kPa)、显著纤维化(>7.9 kPa)和肝硬化(>11.7 kPa)。通过计算受试者工作特征曲线下的面积来估计诊断准确性。
在 582 名未经治疗的患者中,141 名(24.2%)患有显著纤维化,90 名(15.5%)患有肝硬化。天冬氨酸转氨酶与血小板比值指数、FIB-4 和γ-谷氨酰转肽酶与血小板比值的受试者工作特征曲线下面积均较高,可用于诊断显著纤维化(0.79[95%CI 0.75-0.84]、0.79[95%CI 0.75-0.84]、0.80[95%CI 0.75-0.85])和肝硬化(0.86[95%CI 0.81-0.91]、0.86[95%CI 0.81-0.91]、0.87[95%CI 0.82-0.91])。所有测试的特异性均较高(94%-100%);然而,检测纤维化(10%-45%)和肝硬化(10%-36%)的敏感性均较差。
天冬氨酸转氨酶与血小板比值指数、FIB-4 和γ-谷氨酰转肽酶与血小板比值在东非地区具有良好的诊断特性,可用于检测慢性乙型肝炎患者的肝纤维化和肝硬化。然而,敏感性较低,仅用天冬氨酸转氨酶与血小板比值指数在世界卫生组织推荐的阈值下检测到 10%的肝硬化患者。